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Summary
Objective: Methylprednisolone pulses are used in a variety of disease conditions, both for acute and 
chronic therapy. Although well tolerated, they increase glucose levels in both non-diabetic and diabetic 
patients. They may also be considered a significant risk for acute metabolic alterations. The purpose of this 
report is to determine the metabolic changes in blood glucose levels in non-diabetic patients receiving 
methylprednisolone pulses and identify the presence of predictive factors for its development. Methods: 
Observational, prospective study in 50 non-diabetic patients receiving 1 g intravenous methylpredniso-
lone pulses for three consecutive days as an indication for diverse autoimmune disorders. Demographic, 
anthropometric, and metabolic variables were analyzed, and glucose, insulin and C-peptide levels after 
each steroid pulse were identified. Different variables and the magnitude of hyperglycemia were analyzed 
using Pearson’s correlation. Results: 50 patients were included, predominantly women (66%, n = 33). 
The average age was 41 ± 14 years with a BMI of 26 ± 3 kg/m2. Baseline glucose was 83 ± 10 mg/dL. 
After each steroid pulse, glucose increased to 140 ± 28, 160 ± 38 and 183 ± 44, respectively (p < 0.001). 
C-peptide and insulin concentrations increased significantly (p < 0.001). The prevalence of fasting hyper-
glycemia after each pulse was 68%, 94% and 98%, respectively. We found no correlation between the mag-
nitude of hyperglycemia and the studied variables. Conclusion: Methylprednisolone pulses produced 
significant increases in fasting glucose in most patients without diabetes. Further studies are needed to 
define its role in long-term consequences. 
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reSumo
Distúrbios de glicose em pacientes não diabéticos que recebem 
tratamento agudo com pulsos de metilprednisolona 
Objetivo: Pulsos de metilprednisolona são usados em diversas doenças, tanto para tratamento agudo 
quanto crônico. Embora bem tolerados, eles aumentam os níveis de glicose em ambos os pacientes, não 
 diabéticos e diabéticos. Eles também podem ser considerados um risco significativo para alterações me-
tabólicas agudas. O propósito deste estudo é determinar as alterações metabólicas nos níveis de glicose no 
sangue de pacientes não diabéticos que recebem pulsos de metilprednisolona e identificar a presença de 
fatores preditivos para seu desenvolvimento. Métodos: Estudo observacional prospectivo em 50 pacien-
tes não diabéticos que recebem pulsoterapia com 1 g de metilprednisolona intravenosa por três dias con-
secutivos como tratamento para diversas doenças auto imunes. Variáveis demográficas, antropométricas e 
metabólicas foram analisadas, e glicose, insulina e níveis de peptídeo C foram identificados após cada pul-
so de esteroide. Diferentes variáveis e a magnitude da hiperglicemia foram analisadas utilizando a corre-
lação de Pearson. Resultados: 50 pacientes foram incluídos, predominantemente mulheres (66%, n = 33). 
A idade média foi de 41 ± 14 anos com um IMC de 26 ± 3 kg/m2. A glicose de base foi de 83 ± 10 mg/dL. 
Após cada pulso de esteroide, a glicose aumentou para 140 ± 28, 160 ± 38 e 183 ± 44, respectivamente 
(p < 0,001). Peptídeo C e concentrações de insulina aumentaram significativamente (p < 0,001). A pre-
valência de hiperglicemia em jejum após cada pulso foi de 68%, 94% e 98%, respectivamente. Não en-
contramos nenhuma correlação entre a magnitude da hiperglicemia e as variáveis estudadas. Conclusão: 
Os pulsos de metilprednisolona produziram aumentos significativos na glicemia de jejum na maioria 
dos pacientes sem diabetes. Mais estudos são necessários para definir o seu papel nas consequências em 
longo prazo. 
Unitermos: Metilprednisolona; diabetes mellitus; hiperglicemia.
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IntroductIon
Glucocorticoids are compounds that have long been used 
for  a variety of  diseases, both as chronic therapy and in 
acute cases. Methylprednisolone pulses are recommend-
ed for critical events that require urgent treatment for an 
exacerbation of a known disease or when vital organs are 
compromised1.
Although generally well tolerated, they are not free of 
complications such as glucose intolerance, urinary tract 
infections, gastritis, fluid retention, nausea, vomiting, in-
somnia, altered consciousness, joint effusion, abnormal 
taste, hypertension and electrolyte disturbances such as 
hypokalemia2.
Glucocorticoids can worsen known diabetes and pre-
cipitate previously unidentified diabetes3. In all cases, it 
transiently increases up to 50% baseline glucose levels4. An 
OR of 1.36 to 2.31 of de novo diabetes has been reported 
in patients treated with steroids with an incidence of 12%5. 
Steroids can also trigger a severe hyperosmolar hypergly-
cemic decompensation and, in rare cases, death, especially 
in patients with preexisting diabetes6.
The aim of this paper is to present the changes in blood 
glucose levels in non-diabetic Mexican patients undergo-
ing methylprednisolone pulses, and identify factors that 
correlate with the development post-bolus hyperglycemia.
methodS
We performed an observational, longitudinal, prospective 
study in the Medical Specialties “Hospital No. 25 IMSS” 
in Monterrey, Nuevo Leon, from September to November 
2010. We included 50 patients referred by specialists from 
the neurology, rheumatology and hematology services and 
hospitalized in the internal medicine department with the 
therapeutic indication of 1 g pulses of methylprednisolone 
for 3 consecutive days. Inclusion criteria were: individuals 
of both sexes, Mexican, aged 18 years or more and with no 
previous history of DM. The study was approved by the 
institutional ethics committee. 
Demographic, anthropometric and metabolic variables 
were analyzed. Glucose measurements were performed at 
baseline and after each 1 g pulse of intravenous methyl-
prednisolone. We also determined insulin and C-peptide 
levels after each pulse. All examinations were performed 
after 8 hours of fasting. Glucose levels were determined 
by the glucose oxidase method, insulin by electrochemilu-
minescence, and C-peptide levels by chemiluminescence.
The statistical analysis of all data was performed using 
SPSS version 19. The prevalence of post-bolus hypergly-
cemia was calculated. Continuous variables are expressed 
as measures of central tendency and dispersion, and com-
parisons were made using Student’s t-test.  Correlations be-
tween quantitative variables (age, BMI, fasting glucose and 
post-bolus glucose levels) were made with Pearson’s cor-
relation coefficient. A p ≤ 0.05 was considered significant.
reSultS
We included 50 patients with no previous diagnosis of dia-
betes mellitus (DM)5. Gender distribution was 33 women 
(66%) and 17 men (34%). Average age was 41 ± 14 years 
with a BMI of 26 ± 3 kg/m2. Overweight was found in 22 
patients (44%) and obesity in 11 (22%). A family history of 
DM was present in 42%. 
The main diagnoses for patients referred by the attend-
ing physician (blinded to the objectives of the study), were: 
systemic lupus erythematosus (22%), idiopathic thrombo-
cytopenic purpura (24%), multiple sclerosis (22%), auto-
immune hemolytic anemia (8%) and others (18%).
The baseline glucose level was 83  ±  10 mg/dL. After 
each pulse of methylprednisolone, glucose levels increased 
to 140 ± 28 mg/dL, 160 ± 38 mg/dL and 183 ± 44 mg/dL, 
respectively (p  <  0.001). C-peptide and insulin concen-
trations also showed statistically significant increases 
(p < 0.001) (Table 1). 
The prevalence of post-bolus hyperglycemia (glucose 
≥ 126 mg/dL) was: 68% after the first pulse, 94% after the 
second, and 98% after the third pulse. When performing 
Pearson’s correlation we found no predictive factor with 
statistical significance for the development of post-bolus 
hyperglycemia (Table 2).
dIScuSSIon
Pulsed methylprednisolone is highly effective in autoim-
mune diseases due to its anti-inflammatory and immuno-
suppressive effect. It reduces pain and active disease and 
provides acute symptomatic relief, while the beneficial 
effect of other drugs occurs1. The symptomatic benefit of-
fered by steroid pulses causes them to be frequently used 
despite their adverse effects. Our group recently published 
the changes in serum electrolytes in a cohort of patients. 
Without being the objective of that study, we identi-
fied a change in glucose levels7, which had already been 
observed in specific groups of patients in the absence of 
Table 1 – Metabolic changes after methylprednisolone pulses
Variable First pulse Second pulse Third pulse p
Glucose (mg/dL) 140 ± 28 160 ± 38 183 ± 44 < 0.001
C-peptide (ng/mL) 9 ± 2 10 ± 2 11 ± 2 < 0.001
Insulin (µU/mL) 32 ± 10 38 ± 9 43 ± 10 < 0.001
Data are presented as mean and SD.
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diabetes8,9. Mignogna et al. reported that this represents 
the most common complication10, and Feldman-Billard et 
al. identified increases of up to 50% compared to baseline 
levels prior to treatment4.
In our study, we found a significant increase in post-
bolus glucose levels, similar to what has previously been 
reported for non-diabetic patients. This increase was more 
evident after the first pulse with an elevation of about 
40 mg/dL, an increment up to 68% with respect to the bas-
al level. At the end of the third pulse, 98% of the patients 
developed diagnostic criteria for diabetes mellitus, which 
could be explained by a loss of pancreatic islet adaptive 
phenomenon due to an acute and supra-physiological ste-
roid load. In this phenomenon secretion disorders, insulin 
resistance and counterregulatory hormones are involved, 
together with alterations in the secretion and action of 
incretins11. The only patient that did not develop diabe-
tes mellitus criteria presented baseline glucose level below 
54 mg/dL, however the metabolic changes were similar in 
proportion to the total group.
Although the increase is transitory and some authors 
feel that it does not have clinical relevance, there is evi-
dence that identifies acute hyperglycemia as a cardiovas-
cular risk factor, independently of the presence of previous 
diabetes. It has been associated with an increase in LDL 
cholesterol oxidation, impaired endothelial function, ac-
tivation of the coagulation cascade, increased production 
of pro-inflammatory cytokines and oxidative stress3,5,12-14.
The magnitude of the hyperglycemic response has been 
previously associated with age, time and steroid dose, obe-
sity, and in patients with type 2 diabetes mellitus, to poor 
glycemic control5,15. In contrast with previous reports, our 
work shows no link between the different variables stud-
ied. This difference could be explained by genetic and en-
vironmental factors related to the high prevalence of dia-
betes and insulin resistance in our country, confirmed in 
our work by the significant increases in insulin levels.
As an observational non randomized study, we can-
not exclude factors that could influence our results such 
as stress hyperglycemia as well as the inpatient condition. 
However, considering the fact that glycemic levels in-
creased progressively after each pulse, we highly suggest 
that these modifications were due to a cause-effect phe-
nomenon.
Some authors consider it unnecessary to monitor glu-
cose levels in non-diabetic patients because these chang-
es are transient and well tolerated4. We do not know the 
long-term evolution of this expression in our population. 
We suggest monitoring blood glucose levels in all non-
diabetic patients scheduled for methylprednisolone pulse 
therapy, because it is a simple, safe, and inexpensive pro-
cedure. Additionally, we do not know whether these incre-
ments in glucose levels, although transient, could predict 
future diabetes as well as cardiovascular co-morbidities. It 
is important to recall that our results need to be confirmed 
in further observational and randomized studies.
concluSIon
In conclusion, we found that the glucose profile changes 
significantly after the administration of high doses of 
methylprednisolone. BMI, age and baseline glucose levels 
in non-diabetic patients do not correlate with the magni-
tude of hyperglycemia. This alteration requires long-term 
studies to identify the clinical significance of these findings 
in our population.
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